Dresden, July 5, 2024 - DEMECAN is pleased to announce that it has become the first German company to receive a cultivation license for medical cannabis under the new Medical Cannabis Law (MedCanG). This license includes several different phenotypes that DEMECAN will now cultivate for the German market. With this license, DEMECAN can immediately double its production and fully utilize the existing production capacities at the "Cannabis Campus" in Ebersbach. This license allows DEMECAN to achieve an annual yield of approximately 2 tons, with no quantity limit specified.
This license is crucial to meet the growing demand for medical cannabis and marks a
turning point in supply by shifting the focus from imports to more domestic production.
Dr. Adrian Fischer, physician and Managing Director responsible for cultivation,
commented: "This license is a huge step forward for DEMECAN and the entire
industry. We are proud to be the first German company to take this step and look
forward to providing our high-quality cannabis strains soon. Our goal is to further
increase production and thus improve supply security, as there are currently many
shortages in patient care."
The company is also pleased to announce that it achieved strong revenue growth since
April 2024. Dr. Philipp Goebel, Managing Director and responsible for sales, adds:
"The significantly increased demand is reflected in our strong sales and shows that we
are on the right track. The new cultivation permit not only allows us to meet the growing
demand but also enables the sustainable development of our company."
Since its founding in 2017, DEMECAN has established itself as a pioneer in the
German cannabis scene. As the only independent company in Germany covering the
entire value chain for medical cannabis - from cultivation and processing to storage
and delivery to pharmacies - DEMECAN has made a significant contribution to
ensuring patients are supplied with high-quality cannabis products.
The legalization of cannabis on April 1, 2024, has also significantly boosted the market
for medical cannabis, and DEMECAN's new cultivation license sends another positive
signal for the industry. With the expansion of production in Germany, DEMECAN aims
to offer consumers quality-tested products from strictly regulated production.
About DEMECAN
DEMECAN is an independent German company covering the entire value chain of
medical cannabis - from cultivation and pharmaceutical manufacturing to delivery to
pharmacies. The company was founded with the goal of providing patients with highquality access to medical cannabis "Made in Germany."
As the only independent German company, DEMECAN received the contract from the
Federal Institute for Drugs and Medical Devices (BfArM) in May 2019 to grow medical
cannabis in Germany. Cultivation and further processing are carried out according to
the highest pharmaceutical standards at the facility near Dresden. Additionally,
DEMECAN imports medical cannabis from producers worldwide to expand its range
and meet high-quality standards. The company also offers laboratory and processing
services related to medical cannabis.
DEMECAN is a member of the Federal Association of Pharmaceutical Cannabinoid
Companies (BPC) and the Federal Association of the Cannabis Industry (BvCW). With
its commitment to the highest quality and safety in medical cannabis production,
DEMECAN contributes to improving patient care in Germany and Europe.
For more information: www.demecan.de
Press Contact: Franz Großmann
Mail: press@demecan.de
Mobil: +49 151 742 25 332
Ebersbach, Germany, May 2nd, 2023 – Last week, the Saxon company DEMECAN officially filed an application with the Federal Institute for Drugs and Medical Devices (BfArM) to increase the production quantities of medical cannabis in Germany. With the aim of creating equal competition conditions for domestic producers, DEMECAN is calling for an increase in production quantities and an end to the discrimination against German producers.
"There is unequal treatment between German and foreign producers of medical cannabis in Germany," says Dr. Constantin von der Groeben, Managing Director of DEMECAN. "While foreign producers can produce unlimited quantities and import them to Germany, domestic producers such as DEMECAN are only allowed to produce 990 kg. This unequal treatment must now be ended!" adds Dr. von der Groeben.
DEMECAN advocates for higher production of medical cannabis in Germany to ensure the supply of medical cannabis to patients, ensure quality locally, and strengthen the German economy. The company is willing to bear the economic risk for the additional quantities itself and suggests that additional quantities of medical cannabis be awarded through an open-house procedure.
DEMECAN's application follows information from the BfArM from an IFG application for controlling foreign producers exporting medical cannabis to Germany. These revealed that foreign producers are subject to neither quantity nor price restrictions. A small inquiry from the Bundestag fraction DIE LINKE in November 2022 also revealed that permits have now been issued for the import of 78,672.20 kg of dried cannabis flowers, including from Lesotho, Jamaica, and Canada, among others. Permits without quantity restrictions were also granted for North Macedonia.
DEMECAN sees its application as an opportunity to restore competition equilibrium in the industry and strengthen the domestic market. The company remains confident that its application will be positively answered and looks forward to continuing to produce high-quality medical cannabis in Germany.
About DEMECAN
DEMECAN is the only independent German company that covers the entire value chain for medical cannabis – from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in “Made in Germany” quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company’s facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), Cannabis Business Industry Association e.V. (BvCW) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).
Further Information: www.demecan.de
Press contact: press@demecan.de
Currently, the German government is planning to allow controlled supply of cannabis to adults for recreational purposes. According to the Federal Ministry of Health, production will be allowed exclusively in Germany, i.e. the import and export of cannabis products will remain prohibited.
Producers will have to meet certain requirements for qualification, reliability, quality assurance and creditworthiness, which are to be specified in more detail in the draft of the law. There will be specifications on quality and purity, plant protection products, mycotoxins and microorganisms, as well as control systems (track and trace). This means that in the future only quality-tested cannabis products from strictly regulated production will be available on the German market.
We at DEMECAN welcome this very much! It is an important step towards more product quality and at the same time protects the health of the consumers. It is time to push back the illegal market with products without any quality control.
Would you like to learn more about the conditions under which cannabis should be legalized as a stimulant in Germany and what our position is as a manufacturer of medicinal cannabis?
Berlin/Ebersbach, 07. August 2024 - DEMECAN, Germany's premier medical
cannabis producer, is pleased to announce the successful completion of its latest
funding round, marking a significant step forward in its growth strategy. This influx of
capital will enhance pharmacy distribution capabilities through innovative SaaS
solutions and the Company’s online pharmacy platform www.herbery.de. Furthermore,
investments will be made into internationalization and product innovation.
Jörg Sellmann, Managing Director and responsible for finance, adds: "This financing
round is a significant milestone for DEMECAN. It gives us the necessary resources to
accelerate our growth trajectory and capitalize on the burgeoning opportunities within
the medical cannabis sector, especially following its reclassification in April. Demecan
has the best basis for this, as positive results have already been achieved since April
and will improve further due to the full utilization of production capacities in
accordance with the new cannabis law in Germany "
The round, led by Florida-based Trog Hawley Capital, with additional participation from
new and existing investors, represents the first institutional investment from a U.S.
based investor in DEMECAN. Trog Hawley Capital provides capital and strategic
advice to exceptional entrepreneurs and management teams, leveraging over 10 years
of experience building and investing in U.S. multi-state cannabis operators. The
participation of international investors with such experience underscores DEMECAN’s
strength as the market leader, as well as the potential of the German market for
medical cannabis.
"We are pleased with the support of our investors, and their trust in our good work,"
says Dr. Constantin von der Groeben, co-founder and Managing Director of
DEMECAN. "The participation of new investors from the USA shows that our approach
and vision are recognized internationally."
Adam Ryan, CEO of Trog Hawley, adds: " Europe's cannabis market, particularly
Germany, presents exceptional growth prospects far exceeding those in more mature
markets. DEMECAN's comprehensive infrastructure, including its production facilities
and Cannabis Campus with advanced laboratory and processing capabilities, positions
it as a frontrunner in the industry. We are very excited to be part of the team and look
forward to supporting their next growth phase."
About DEMECAN
DEMECAN is an independent German company that covers the entire value chain of
medical cannabis - from cultivation through pharmaceutical production to delivery to
pharmacies. The company was founded in 2017 and has since established itself as a
pioneer in the German cannabis market. With its commitment to the highest quality and safety in medical cannabis production, DEMECAN contributes to improving patient care in Germany and Europe.
In May 2019, DEMECAN received the contract to grow medical cannabis in Germany from the Federal Institute for Drugs and Medical Devices (BfArM). Cultivation and processing are carried out according to the highest pharmaceutical standards at the facility near Dresden. In July 2024, DEMECAN also received a cultivation license under the new Medical Cannabis Act. In addition, DEMECAN imports medical cannabis from producers worldwide to expand its range and meet high-quality standards. The company also offers laboratory and processing services related to medical cannabis and provides pharmacies with a logistics solution for handling medical cannabis.
DEMECAN is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and the Federal Association of the Cannabis Industry (BvCW).
About Trog Hawley Capital
Founded in 2012 and based in West Palm Beach, Florida, Trog Hawley Capital leverages a team of serial entrepreneurs, seasoned operators, and investment professionals who collectively have founded and grown businesses worth over $1 billion. Trog Hawley Capital founded, and operated Tryke Companies, a multi-state cannabis operator, for nearly a decade, eventually exiting the business via sale to a strategic acquirer in late-2022. The firm has carved its niche in direct venture investing with 30+ portfolio companies across verticals such as big data, cyber security, cannabis, e-commerce, energy infrastructure, enterprise, fintech, gaming/esports, and healthtech.
For more information: www.demecan.de
Press contact: Franz Großmann
Email: press@demecan.de
Mobile: +49 151 742 25 332
Berlin/Dresden, Germany, December 19, 2022 – DEMECAN, the only independent vertically-integrated cannabis company in Germany, successfully closes its current funding round. The company raised capital totaling EUR 15 million in 2022, consisting of loans and equity financing.
The funding will finance the further expansion of the company, including to increase production capacity at the facility in Ebersbach near Dresden/Saxony. Here, cannabis services, such as the processing of cannabis flower, are also offered to third parties. In addition, the expansion is part of the company’s preparations for the upcoming legalization of cannabis for recreational use. However, the company also remains active in the field of medical cannabis and is pushing ahead with research and development. Recently, the company’s cell culture laboratory at the Ebersbach site produced its first plants from tissue culture.
The investment in this funding round comes from private and institutional investors. Both existing shareholders and new investors are supporting the company in its further entrepreneurial development. Among others, Mittelständische Beteiligungsgesellschaft Sachsen (MBG) and the Swedish dedicated Cannabis fund ENEXIS AB are joining existing shareholders, including the Frankfurt-based funds Futury Growth and Futury Venture as well as btov’s Private Investor Network as investors in DEMECAN, thus participating in one of Saxony's leading start-ups’ expansion course.
"DEMECAN pursues the mission of supplying the German market with high-quality medical cannabis and contributing to the security of supply for patients. We also have the legalization of recreational cannabis in mind. The value chain of cannabis will probably have to be fully mapped in Germany. This will bring new challenges but great opportunities for us as a vertically integrated cannabis company and we are already preparing today for it" comments Jörg Sellmann, member of DEMECAN’s executive board.
MBG sees the investment in DEMECAN as an opportunity to foster a still young and future-proved German market from Saxony. “Our funding for DEMECAN makes sense in several ways. We have been following the development of the Ebersbach production facility from the very beginning. Now is the right time for us to invest. DEMECAN has exciting times ahead, as markets develop further. The demand for cannabis will keep increasing in the near future. The number of Cannabis patients is growing, and the legalization of recreational cannabis is on the way", says Markus H. Michalow, Managing Director of MBG. "We are proud to play a part in the further development of this forward-looking company here in Saxony", he continued.
About DEMECAN
DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).
Further Information: www.demecan.de
Press contact: press@demecan.de
